Westergaard 2015

Methods	Country: Denmark Aim: To evaluate the effect of varenicline on tobacco cessation in young smokers suffering from asthma Dates conducted: Not stated Study Design: Double‐blind placebo‐controlled RCT
Participants	52 young (aged 19 ‐ 40) smokers with asthma, randomised to varenicline (26) or placebo (26). CPD ≥ 10; FTND 5.6
Interventions	1. Varenicline: presumed standard regimen: Varenicline 1.0 mg x 2/day 2. Placebo tablet x 2/day No further details
Outcomes	Primary: presumed PPA at 12 wks Secondary: presumed PPA at 0, 6, 24 wks Validation by expired CO < 10 ppm Also assessed asthma symptom score, general health quality score (15D) and methacholine challenge
Treatment type	Medication: VARENICLINE
Notes	Author supplied further details
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated. ""randomized, placebo‐controlled, double‐blinded trial"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not stated. "double‐blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not stated; ITT analysis conducted
Selective reporting (reporting bias)	Unclear risk	Not stated
Other bias	Unclear risk	Not stated